Scholar Rock Holding Corporation
SRRK
株式のランク
#3426
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
株価
$41.58
最終同期: 2026-10-20
時価総額
$5.06B
変化（1日）
3.34%
変化（1年）
47.62%
国
US
取引 Scholar Rock Holding Corporation (SRRK)
カテゴリー
Healthcare
Scholar Rock Holding Corporation（SRRK）の発行済株式数
June 2026 時点の発行済株式数 130.61M
Scholar Rock Holding Corporation の最新の財務報告および株価によると、現在の発行済株式数は 130.61M です。December 2023 の終わりには、同社は 75.98M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Scholar Rock Holding Corporation（SRRK）の発行済株式数の履歴（2016 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 130.61M | 30.82% |
| 2024 | 99.84M | 31.40% |
| 2023 | 75.98M | 27.46% |
| 2022 | 59.61M | 62.38% |
| 2021 | 36.71M | 19.45% |
| 2020 | 30.73M | 11.61% |
| 2019 | 27.54M | 75.90% |
| 2018 | 15.66M | -12.57% |
| 2017 | 17.91M | 0.00% |
| 2016 | 17.91M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 94.39% |
US
|
|
| 396.00M | 203.19% |
US
|
|
| 478.91M | 266.67% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.39% |
NL
|
